Jun 3 |
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven?
|
May 24 |
YS Biopharma Announces Name Change to LakeShore Biopharma
|
May 7 |
YS Biopharma appoints Dave Chenn as interim CEO
|
May 7 |
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
|
May 7 |
With 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's future
|
Apr 22 |
YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript
|
Apr 18 |
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
|
Apr 16 |
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
|
Apr 9 |
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
|
Apr 3 |
YS Biopharma announces full repayment of $40M loan facility
|